Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Free Cash Flow (2016 - 2025)

Aptevo Therapeutics' Free Cash Flow history spans 11 years, with the latest figure at -$6.7 million for Q3 2025.

  • For Q3 2025, Free Cash Flow fell 28.0% year-over-year to -$6.7 million; the TTM value through Sep 2025 reached -$26.1 million, down 12.42%, while the annual FY2024 figure was -$23.8 million, 102.77% down from the prior year.
  • Free Cash Flow for Q3 2025 was -$6.7 million at Aptevo Therapeutics, up from -$7.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $4.6 million in Q1 2023 and bottomed at -$7.7 million in Q1 2021.
  • The 5-year median for Free Cash Flow is -$5.8 million (2024), against an average of -$5.2 million.
  • The largest annual shift saw Free Cash Flow surged 189.23% in 2023 before it crashed 246.74% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$4.0 million in 2021, then crashed by 48.55% to -$5.9 million in 2022, then rose by 11.55% to -$5.3 million in 2023, then fell by 10.13% to -$5.8 million in 2024, then decreased by 15.06% to -$6.7 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Free Cash Flow are -$6.7 million (Q3 2025), -$7.1 million (Q2 2025), and -$6.6 million (Q1 2025).